ClinicalTrials.gg
Active, not recruitingNCT07061938Updated Nov 17, 2026

Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects With IgG4-Related Disease

A Phase 1/2 interventional study of ACE1831 and Lymphodepleting chemotherapy in IgG4 Related Disease, sponsored by Acepodia Biotech, Inc.. Active, not recruiting at 11 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.

Sponsored by Acepodia Biotech, Inc. · Phase 1/2, Interventional, and Treatment

How we know

Updated Nov 17, 2026Now Active, not recruitingFirst site in China+7 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
34
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 41 studies in Immunoglobulin G4-Related Disease with a site in China — 24 open to participants now, 28 under way, 5 of them phase 3. Immunoglobulin G4-Related Disease · China.

Planned enrollment
24th of 37
34 · median 58
Started
2026
with 6 others
Phase 1/2
Only one
of the 41
Primary completion
2029-09
later than 23 of 27 live
Registered
29th of 41
by date
Lead sponsor
1 of 41
Acepodia Biotech, Inc.

Among the 41 studies in Immunoglobulin G4-Related Disease with a site in China, this one is the 24th largest by planned enrollment of the 37 interventional ones that give a count, is one of 7 that started in 2026, is the only one in phase 1/2, reaches primary completion later than 23 of the 27 other live ones, and was the 29th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

24 of the 41 studies in Immunoglobulin G4-Related Disease with a site in China are open now. Recruiting first, the newest first:

19 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 41 studies in Immunoglobulin G4-Related Disease with a site in China, or all of them as a file.
02

Study summary

ACE1831 is an off-the-shelf, allogeneic gamma delta T (gdT) cell therapy derived from healthy donors, that is under investigation for the treatment in subjects with Immunoglobulin G4 Related Disease (IgG4-RD)

Read the detailed description

ACE1831-201 study is an Open Label, Multicenter, Two Arm Study to Assess Safety, Efficacy and Persistence of ACE1831, in Subjects with Immunoglobulin G4-Related Disease

03

Conditions studied

  • IgG4 Related Disease

Keywords

  • IgG4 Related Disease
  • cell therapy
  • IgG4-RD
  • ACE1831
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Inclusion Criteria: To be eligible for this study, all of the following inclusion criteria must be met:

  • Signed
  • Male or female ≥ 18 years of age
  • Active IgG4-RD flare at screening with IgG4-RD Responder Index at least 2, confirmed by symptoms, labs, and/or imaging.
  • History of IgG4-RD involving at least 2 organs/sites, and current flare involves at least 1 organ/site (excluding lymph nodes) requiring treatment.
  • Elevated serum IgG4 above the at screening.
  • Able to receive for current flare and taper to 0 mg by Day -5.
  • agreement per protocol from screening through 24 weeks after last ACE1831 dose (no LDC) or 12 months after last LDC dose (with LDC).
  • For sites in China only: prior treatment failure to glucocorticoids, one agent and one biologic agent.

Exclusion Criteria: An individual who meets any of the following criteria will be excluded from participation in this trial.

  • Significant conditions that impair ability to receive study treatment or comply.
  • Predominant fibrosis in affected organs.
  • Active/latent infection that would interfere with therapy (including , , , TB, syphilis) or significant recent infection per protocol.
  • Known immunodeficiency state.
  • class III/IV heart disease.
  • Severe allergy/ to monoclonal antibodies or relevant study agents.
  • within 5 years (protocol exceptions apply).
  • Recent agent exposure.
  • Recent B-cell depleting therapy (anti-CD20/anti-CD19) unless reconstitution per protocol.
  • Live/attenuated vaccine within 2 months.
  • Pregnant or breastfeeding.
  • Inadequate organ function/blood counts per protocol.
Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    Arm A

    * Cohort A1: Receives single infusion of ACE1831 (Dose Level 1) with lymphodepletion conditioning (LDC). * Cohort A2: Receives single infusion of ACE1831 (Dose Level 2) with LDC.

    Drug: ACE1831 · Drug: Lymphodepleting chemotherapy

  • Experimental
    Arm B

    * Cohort B1: Receives two infusions of ACE1831 (Dose Level 1) without LDC. * Cohort B2: Receives two infusions of ACE1831 (Dose Level 2) without LDC. * Cohort E (Expansion): Two infusions of ACE1831 at the dose/regimen selected by the Safety Review Committee (SRC)

    Drug: ACE1831

Interventions

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital Signs

    Primary Outcome Measures: Safety and Tolerability of ACE1831. Adverse Events: Incidence of TEAEs, SAEs, AESIs, and DLTs. Clinical Laboratory Abnormalities: Number of subjects with clinically significant abnormalities in protocol-defined clinical laboratory assessments compared with baseline. Physical Examination Abnormalities: Number of subjects with clinically significant changes from baseline. ECG Abnormalities: Number of subjects with clinically significant ECG changes (PR, QRS, QT/QTcF, heart rate) from baseline. Vital Signs Abnormalities: Number of subjects with clinically significant changes from baseline. Number of Subjects With Clinically Significant Changes in Vital Signs From Baseline. Number of subjects with clinically significant changes in vital signs, including temperature, respiratory rate, heart rate, blood pressure, and oxygen saturation (SpO₂), compared with baseline. For all of the above, Unit of Measure: Number of Subjects

    Time frame: up to 72 weeks post first-ACE1831 dose

Secondary outcomes

  1. To assess the efficacy of ACE1831 (primary efficacy)

    • Proportion of subjects in complete remission 24 weeks after first dose of ACE1831

    Time frame: 24 weeks after last dose of ACE1831

  2. 3.1 To assess the efficacy of ACE1831 (secondary efficacy): Proportion of subjects who experience sustained complete remission

    Proportion of subjects who experience complete remission 72 weeks after the first dose of ACE1831

    Time frame: up to 72 weeks post-first ACE1831 dose

  3. 3.2 To assess the efficacy of ACE1831 (secondary efficacy): Time to first confirmed flare

    Time (days) from first dose of ACE1831 to first confirmed flare

    Time frame: up to 72 weeks post-first ACE1831 dose

  4. 3.3 To assess the efficacy of ACE1831 (secondary efficacy): Cumulative GC usage

    Cumulative GC usage (milligrams) at at 24, 48 and 72 weeks after the first dose of ACE1831

    Time frame: up to 72 weeks post-first ACE1831 dose

  5. 3.4 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SF-12

    Changes in Quality of Life Questionnaire (QOL) Short Form 12 (SF-12) total score

    Time frame: up to 72 weeks post-first ACE1831 dose

  6. 3.5 To assess the efficacy of ACE1831 (secondary efficacy): Changes in PGA

    Changes in Physician's Global Assessment (PGA) of disease activity score (Visual Activity Score, scale range 0 -100)

    Time frame: up to 72 weeks post-first ACE1831 dose

  7. 3.6 To assess the efficacy of ACE1831 (secondary efficacy): Time to PGA = 0

    Time (days) to PGA assessment score of 0

    Time frame: up to 72 weeks post first-ACE1831 dose

  8. 3.7 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SGA

    Changes in Subject's Global Assessment (SGA) of disease activity score (Visual Activity Score, scale range 0 - 100)

    Time frame: up to 72 weeks post first-ACE1831 dose

  9. 3.8 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SSI

    Changes in IgG4-RD symptom severity index (IgG4-RD-SSI) score

    Time frame: up to 72 weeks post first-ACE1831 dose

  10. 3.9 To assess the efficacy of ACE1831 (secondary efficacy): Changes in IgG4-RD RI

    Changes in IgG4-RD Responder Index (IgG4-RD RI) score

    Time frame: up to 72 weeks post first-ACE1831 dose

07

Study locations

11 sites
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started Jan 2026 (actual). Primary completion is estimated for Sep 2029, 44 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 2, 2026: primary completion Jan 2027 → Sep 2029 and completion Jun 2027 → Sep 2029.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
May 27, 2025
First posted
Jul 14, 2025
StartActual
Jan 1, 2026
Primary completionEst.
Sep 20, 2029was Jan 2027
CompletionEst.
Sep 20, 2029was Jun 2027
Last update
Nov 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Nov 17, 2026
Sites
8 sites added — first site in China
Show 8 added (8 China)
  • Beijing Friendship Hospital · Beijing, China
  • Peking Union Medical College Hospital · Beijing, China
  • Sichuan University - West China Hospital · Chengdu, China
  • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
  • The First Affiliated Hospital-University of Science and Technology of China · Hefei, China
  • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
  • Bethune Hospital Shanxi Academy of Medical Sciences · Taiyuan, China
  • Huazhong University of Science and Technology-Tongji Hospital (TJH) · Wuhan, China
Oct 2, 2026
Primary completion
Jan 20, 2027→Sep 20, 2029
Oct 2, 2026
Study completion
Jun 20, 2027→Sep 20, 2029
Oct 2, 2026
Enrollment
30→34
Oct 2, 2026
Eligibility
Maximum age 75 Years→none; 2 criteria edited
What changed in the criteria
  • EditedMale or female ≥ 18 to 75 years of age
  • EditedFor sites in China only: prior treatment failure to glucocorticoids and at least, one immunosuppressive agent and one biologic agent.
Oct 2, 2026
Interventions
Arms added: Arm A·Arm B; arms removed: Single Arm trial
Oct 2, 2026
Primary outcomes
1 time frame changed
What changed in the outcomes
  • Time frameSafety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital Signsup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
Oct 2, 2026
Secondary outcomes
1 edited, 8 time frame changed, 3 description edited
What changed in the outcomes
  • Edited3.2 To assess the efficacy of ACE1831 (secondary efficacy): Time to first confirmed flareTime frame: up to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
  • Time frame3.1 To assess the efficacy of ACE1831 (secondary efficacy): Proportion of subjects who experience sustained complete remissionup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
  • Time frame3.3 To assess the efficacy of ACE1831 (secondary efficacy): Cumulative GC usageup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
  • Time frame3.4 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SF-12up to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
  • Time frame3.5 To assess the efficacy of ACE1831 (secondary efficacy): Changes in PGAup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
  • Time frame3.6 To assess the efficacy of ACE1831 (secondary efficacy): Time to PGA = 0up to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
  • Time frame3.7 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SGAup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
  • Time frame3.8 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SSIup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
  • Time frame3.9 To assess the efficacy of ACE1831 (secondary efficacy): Changes in IgG4-RD RIup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
  • Description3.1 To assess the efficacy of ACE1831 (secondary efficacy): Proportion of subjects who experience sustained complete remission: how it is measured was reworded
  • Description3.3 To assess the efficacy of ACE1831 (secondary efficacy): Cumulative GC usage: how it is measured was reworded
  • DescriptionTo assess the efficacy of ACE1831 (primary efficacy): how it is measured was reworded
Oct 2, 2026
Site contacts
Changed at 3 sites. See the sites
Show 3 sites
  • Emory University · Atlanta, United StatesContact removed j•••@emory.edu · •••2886
  • Massachusetts General Hospital · Boston, United StatesContact removed j•••@mgh.harvard.edu · •••7938
  • Kanazawa Medical University Hospital · Kahoku-gun, JapanContact removed y•••@kanazawa-med.ac.jp · •••3511Contact removed y•••@kanazawa-med.ac.jp
Oct 2, 2026
Show all 2 updates
  1. Nov 17, 2026
    Recruiting→Active, not recruiting
    + 2 other changes: contact details and site details
  2. Oct 2, 2026
    8 sites added — first site in China
    Show 8 added (8 China)
    • Beijing Friendship Hospital · Beijing, China
    • Peking Union Medical College Hospital · Beijing, China
    • Sichuan University - West China Hospital · Chengdu, China
    • The Second Affiliated Hospital of Zhejiang University School of Medicine · Hangzhou, China
    • The First Affiliated Hospital-University of Science and Technology of China · Hefei, China
    • Renji Hospital Affiliated to Shanghai Jiaotong University School of Medicine · Shanghai, China
    • Bethune Hospital Shanxi Academy of Medical Sciences · Taiyuan, China
    • Huazhong University of Science and Technology-Tongji Hospital (TJH) · Wuhan, China
    Primary completion Jan 20, 2027→Sep 20, 2029
    Study completion Jun 20, 2027→Sep 20, 2029
    Enrollment 30→34
    Eligibility Maximum age 75 Years→none; 2 criteria edited
    What changed in the criteria
    • EditedMale or female ≥ 18 to 75 years of age
    • EditedFor sites in China only: prior treatment failure to glucocorticoids and at least, one immunosuppressive agent and one biologic agent.
    Primary outcomes 1 time frame changed
    What changed in the outcomes
    • Time frameSafety and Tolerability of ACE1831 as Assessed by Adverse Events, Clinical Laboratory Tests, Physical Examinations, ECGs, and Vital Signsup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
    Secondary outcomes 1 edited, 8 time frame changed, 3 description edited
    What changed in the outcomes
    • Edited3.2 To assess the efficacy of ACE1831 (secondary efficacy): Time to first confirmed flareTime frame: up to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
    • Time frame3.1 To assess the efficacy of ACE1831 (secondary efficacy): Proportion of subjects who experience sustained complete remissionup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
    • Time frame3.3 To assess the efficacy of ACE1831 (secondary efficacy): Cumulative GC usageup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
    • Time frame3.4 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SF-12up to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
    • Time frame3.5 To assess the efficacy of ACE1831 (secondary efficacy): Changes in PGAup to 72 weeks post-last ACE1831 dose → up to 72 weeks post-first ACE1831 dose
    • Time frame3.6 To assess the efficacy of ACE1831 (secondary efficacy): Time to PGA = 0up to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
    • Time frame3.7 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SGAup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
    • Time frame3.8 To assess the efficacy of ACE1831 (secondary efficacy): Changes in SSIup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
    • Time frame3.9 To assess the efficacy of ACE1831 (secondary efficacy): Changes in IgG4-RD RIup to 72 weeks post last-ACE1831 dose → up to 72 weeks post first-ACE1831 dose
    • Description3.1 To assess the efficacy of ACE1831 (secondary efficacy): Proportion of subjects who experience sustained complete remission: how it is measured was reworded
    • Description3.3 To assess the efficacy of ACE1831 (secondary efficacy): Cumulative GC usage: how it is measured was reworded
    • DescriptionTo assess the efficacy of ACE1831 (primary efficacy): how it is measured was reworded
    Interventions Arms added: Arm A·Arm B; arms removed: Single Arm trial
    Site contacts Changed at 3 sites. See the sites
    Show 3 sites
    • Emory University · Atlanta, United StatesContact removed j•••@emory.edu · •••2886
    • Massachusetts General Hospital · Boston, United StatesContact removed j•••@mgh.harvard.edu · •••7938
    • Kanazawa Medical University Hospital · Kahoku-gun, JapanContact removed y•••@kanazawa-med.ac.jp · •••3511Contact removed y•••@kanazawa-med.ac.jp
    + 4 other changes: identifiers, verification date, description and design details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07061938
Lead sponsor
Acepodia Biotech, Inc.
Responsible party
Sponsor
First posted
Jul 14, 2025
Start date
Jan 1, 2026
Primary completion
Sep 20, 2029 (estimated)
Completion
Sep 20, 2029 (estimated)
Last update
Nov 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Allogeneic Rituximab Conjugated Gamma Delta T-cells ACE1831

Start the discussion